| Background: Cucurbitacin,a kind of tetracyclic triterpenoid,which distributes widely in many branches such as Rutaceae or Scrophulariaceae.Cucurbitacin C is a member of the cucurbitacin family,anticancer activity and mechanism of the compound have not been reported yet.This project will study the Inhibition of cucurbitacin C on liver cancer and prostate cancer cells and the related mechanisms by multiple methods including MTT assay,flow cytometry and m RNA sequencing.Methods: In this study,liver cancer Hep G2 and prostate cancer PC-3 cell lines were selected for cell proliferation(MTT)assay,cell colony formation assay,and cell scratch assay to verify drug anticancer activity.Flow cytometry and Western blot were used to determine changes on cell cycle and apoptosis.RNA sequence and Western blot experiments were used to determine the molecular mechanism of drug action.Results: These results show that cucurbitacin C has the ability to inhibit the activity of liver cancer Hep G2 and prostate cancer PC-3 cells in vitro,including the cell proliferation,cloning and migration,and the effect is more obvious with drug concentration increasing.In addition,under affecting of low-dose cucurbitacin C,the cell cycle of Hep G2 was arrested in G2/M phase,while PC-3 was arrested in G1 phase,and some key cycle protein expressions such as cyclin A and D1 changed.A high dose of drugs causes apoptosis increasing.Further analysis of molecular mechanism revealed that under cucurbitacin C affected,the Akt signaling pathways of both cancer cells changed,and the phosphorylation of the key signaling factor Akt was significantly inhibited.Conclusion: Cucurbitacin C has anti-cancer potential,can cause cell cycle arrest and apoptosis of liver cancer and prostate cancer cells in vitro,which leads to inhibition of cell activity.About molecular mechanism,Cucurbitacin C affects the Akt signaling pathway by multiple ways including inhibits Akt protein phosphorylation. |
PDF Full Text Request